- Completed
NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma
Sponsor:
Kartos Therapeutics, Inc.
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT01723020
Official Title: A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
First Posted : November 7, 2012
Click here for details on ClinicalTrials.gov
Drug: AMG 232
Navtemadlin (Code C116624)
AMG 232
AMG-232
KRT 232
KRT-232
KRT232
MDM2 Inhibitor KRT-232
Navtemadlin
NAVTEMADLIN
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
Invest New Drugs;2020
Per local review, there were no responses. Stable disease (durability in months) was observed in patients with WDLPS (3.9), OST (3.3), DDLPS (2.0), GBM (1.8), and BC (1.4-2.0). Conclusions In patients with P53WT advanced solid tumors or MM, AMG 232 showed acceptable safety and dose-proportional pharmacokinetics, and stable disease was observed.